Amgen Q2 FY26 GAAP EPS rises 65% to $4.37; revenue increases 10% to $10.1 billion

• Amgen Q2 2026 revenue rose 10% to $10.1 billion; GAAP diluted EPS jumped 65% to $4.37.
• GAAP operating income climbed to $3.5 billion; operating margin widened 6.5 percentage points to 36.8%.
• Free cash flow increased to $3.5 billion from $1.9 billion, reflecting the final repatriation tax payment in Q2 2025.
• Repatha sales rose 37% to $953 million; Prolia sales fell 32% to $759 million as multiple biosimilars launched globally.
• 2026 guidance: revenue $38.2 billion-$39.4 billion; GAAP EPS $15.80-$17.08; non-GAAP EPS $22.30-$23.50.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amgen Inc. published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein.